We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2012 by Sivakami A Pai, Dubai Health Authority.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01707745
First Posted: October 16, 2012
Last Update Posted: October 16, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Sivakami A Pai, Dubai Health Authority
  Purpose

Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In retinopathy of prematurity (ROP).

Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II.


Condition Intervention
Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II. Procedure: Intravitreal Bevacizumab

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Sivakami A Pai, Dubai Health Authority:

Primary Outcome Measures:
  • Regression Of ROP [ Time Frame: Minimum 6 months follow up after intravitreal Avastin ]

Secondary Outcome Measures:
  • Recurrence of ROP [ Time Frame: minimum 6 months of follow up. ]

Estimated Enrollment: 50
Study Start Date: January 2010
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Avastin
Bevacizumab(Avastin) 0.75mg in 0.03 ml
Procedure: Intravitreal Bevacizumab
Other Name: Intravitreal Avastin

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   32 Weeks to 42 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: stage 2+ or stage 3+ Retinopathy of prematurity in Zone I or Zone II.

Informed written consent by parents or guardian.

Exclusion Criteria:

Refusal to give consent Critically ill neonates.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01707745


Contacts
Contact: Sivakami A Pai, MS, DNB, Phd 00971504148256
Contact: M A Dekhain, FRCS, MRCOpth 0097142195000 ext 6272 maDekhain@dha.gov.ae

Locations
United Arab Emirates
Dubai Hospital Recruiting
Dubai, UAE, United Arab Emirates
Contact: Sivakami A Pai, MS, DNB, Phd    00971504148256      
Contact: Moza A Dekhain, MRCOpthal, FRCS    009712195000 ext 6272    maDekhain@dha.gov.ae   
Principal Investigator: Sivakami A Pai, MS, DNB, Phd         
Sub-Investigator: Afra M Lootah, MSc, FRCS         
Sponsors and Collaborators
Sivakami A Pai
  More Information

Responsible Party: Sivakami A Pai, Doctor, Dubai Health Authority
ClinicalTrials.gov Identifier: NCT01707745     History of Changes
Other Study ID Numbers: Avastin for threshold ROP.
First Submitted: September 22, 2012
First Posted: October 16, 2012
Last Update Posted: October 16, 2012
Last Verified: October 2012

Additional relevant MeSH terms:
Retinopathy of Prematurity
Retinal Diseases
Eye Diseases
Infant, Premature, Diseases
Infant, Newborn, Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents